Gene · 1830
Papers2,614
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 2,614
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Factors associated with persistent anti-desmoglein positivity after remission in pemphigus vulgaris: a prospective registry-based cohort study. | Front Immunol | 2025 | 40433384 | PubTator, text mining | PubMed |
| Immunohistochemistry for Skin Cancers: A Comprehensive Approach to the Diagnosis of Squamous Cell Carcinoma. | Cancers (Basel) | 2025 | 40427131 | PubTator, text mining | PubMed |
| Autoimmune bullous diseases: pathogenesis and clinical management. | Mol Biomed | 2025 | 40372624 | PubTator, text mining | PubMed |
| A Bidirectional Two-Sample Mendelian Randomization Study of Genetic Causality Between Vitamin D Levels and Pemphigus. | Clin Cosmet Investig Dermatol | 2025 | 40370580 | PubTator, text mining | PubMed |
| Correlating pemphigus disease area index (PDAI) severity categories with oral disease severity score (ODSS) in oral mucosal pemphigus - A pilot study. | Indian J Dermatol Venereol Leprol | 2025 | 40357941 | PubTator, text mining | PubMed |
| Elevated Fab glycosylation of autoantibodies maintained during B cell depletion therapy. | Sci Rep | 2025 | 40295683 | PubTator, text mining | PubMed |
| [CAR-T cells in Dermatology: Mechanisms of action and applications in autoimmune diseases]. | Rev Med Inst Mex Seguro Soc | 2025 | 40279442 | PubTator, text mining | PubMed |
| Direct inhibition precedes p38 mitogen activated protein kinase-mediated uncoupling in desmosomes to reduce desmoglein 3 adhesion by pemphigus autoantibodies. | Br J Dermatol | 2025 | 40264374 | PubTator, text mining | PubMed |
| Epitomic profiling and functional characteristics of pemphigus vulgaris autoantibody binding to keratinocyte M3 muscarinic acetylcholine receptor. | J Biol Chem | 2025 | 40120680 | PubTator, text mining | PubMed |
| Comparison of clinical efficacy and cost-effectiveness of rituximab infusion and intravenous dexamethasone pulse therapy in pemphigus vulgaris: an open prospective randomized controlled pilot study. | Clin Exp Dermatol | 2025 | 40100754 | PubTator, text mining | PubMed |
| Antidesmoglein 1 and 3 serum IgG and positivity by direct immunofluorescence microscopy is associated with relapse in pemphigus in a prospective bicontinental study. | JAAD Int | 2025 | 40084347 | PubTator, text mining | PubMed |
| Can the count and percentage of immature granulocytes be used to detect disease activity in patients with pemphigus?: A preliminary study. | Medicine (Baltimore) | 2025 | 40068041 | PubTator, text mining | PubMed |
| Clinical Features, Diagnosis and Treatment of Different Types of Paediatric Pemphigus. | Acta Derm Venereol | 2025 | 40059466 | PubTator, text mining | PubMed |
| Molecular Markers of Occult Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients. | Front Biosci (Landmark Ed) | 2025 | 40018925 | PubTator, text mining | PubMed |
| Integrative Analysis of Cuproptosis-Related Mitochondrial Depolarisation Genes for Prognostic Prediction in Non-Small Cell Lung Cancer. | J Cell Mol Med | 2025 | 40008552 | PubTator, text mining | PubMed |
| In vitro and ex vivo models of the oral mucosa as platforms for the validation of novel drug delivery systems. | J Tissue Eng | 2025 | 39944725 | PubTator, text mining | PubMed |
| Diagnostic methods and strategies for autoimmune bullous diseases. | Expert Rev Clin Immunol | 2025 | 39930606 | PubTator, text mining | PubMed |
| Ephrin-Eph signaling: an important regulator of epithelial integrity and barrier function. | Tissue Barriers | 2025 | 39921660 | PubTator, text mining | PubMed |
| Pemphigus Vulgaris Autoantibodies Induce an Endoplasmic Reticulum Stress Response. | J Invest Dermatol | 2025 | 39909113 | PubTator, text mining | PubMed |
| Optimizing Pemphigus Management With Rituximab and Short-Term Relapse Predictors. | JAMA Dermatol | 2025 | 39908046 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1830/papers?page=6